GUARDIAN PHARMACY SERVICES INC CLA (GRDN)
Health Care · Pharmacy Services · NYSE
Guardian Pharmacy Services provides specialized pharmacy and medication management solutions for long-term care facilities.
What GUARDIAN PHARMACY SERVICES INC CLA does
Guardian Pharmacy Services operates a network of pharmacies that specialize in providing pharmaceutical services and medication management for long-term care facilities (LTCFs). The company focuses on dispensing medications, providing consulting pharmacy services, and integrating pharmacy operations with the clinical needs of residents in long-term care settings.
Themes: long-term care pharmacy, medication management
Fundamentals
- Price$37.93 as of 2026-08-21 close
- Market cap$2.4B as of 2026-08-24
- 1-year return+44.3% 2025-08-21 close $26.29 → 2026-08-21 close $37.93
- P/E45.91 as of 2026-08-24
- Net margin+3.6% as of 2026-08-24
- Gross margin+20.9% as of 2026-08-24
- ROE+27.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+11.3% as of 2026-08-24
- Beta0.49 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How GRDN compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
GRDN is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
44.2 #1179 of 1,704 scored · #195 of 240 in Health Care
Volume and participation 84th: trading volume is about normal versus its 30-day average; momentum 41st: near the bottom of its 14-day range (oversold); weakest is catalysts 33rd: open-market insider buys in 90 days 0, analysts' average price target is unchanged from the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How GUARDIAN PHARMACY SERVICES INC CLA looks technically
GUARDIAN PHARMACY SERVICES INC CLA (GRDN) is trading 7.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 244 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 8, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 19.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 7.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $40.51 | $40.51 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.21 | $35.21 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 244 trading days ago — a "golden cross", a bullish long-term signal | 244 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 8, below the 25 that marks a real trend) | 8.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 42.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($36.90 to $47.02) — its "stochastic" reading is 10 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 10.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $47.02 | $47.02 |
|---|---|---|
| From the 52-week high | it is 19.3% below its 52-week high (its highest price of the past year) | -19.3% |
| Above the 52-week low | it is 63.9% above its 52-week low (its lowest price of the past year) | +63.9% |
| Below the 52-week high | it is 19.3% below its highest point of the past year | 19.3% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $47.02 (set on 2026-08-07) | $47.02 |
| Given back of the 52-week move | over the past year its closes ranged ($23.41 to $43.83), and it has given back roughly a quarter of its rise from last year’s low — 29% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $30.56 to $31.21. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 28.9% |
| From the all-time high | it is 19.3% below its all-time high | -19.3% |
| Nearest price level | it is sitting right on a resistance level at $38.12 — a price it turned at twice since 2026-03-23, most recently on 2026-06-26. Since 2024-09-26 it has 14 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.5% |
| All-time low | its lowest closing price on record is $14.16 (set on 2024-09-26) | $14.16 |
| Above the all-time low | it is 167.9% above its all-time low | +167.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.83 between its high and its low — about 4.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.83 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $36.50 and $43.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $36.50 – $39.81 – $43.12 |
| Typical daily range (% of price) | its price moves about 4.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges above its 200-day average price (7.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.19× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 9.3% gap up opened on 2026-08-07 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 8 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.6 percentage points (the stock lost 7.3% while the market gained 2.3%) | -9.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.2 percentage points (the stock lost 1.1% while the market gained 3.1%) | -4.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 2.0 percentage points (the stock gained 13.1% while the market gained 11.1%) | +2.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 23.8 percentage points (the stock gained 44.3% while the market gained 20.5%) | +23.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.5% of the share price. | -0.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $37.25 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +1.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $39.86 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -4.8% |
Price levels it has turned at before
GRDN last closed at $37.93 on 2026-08-21. Since 2024-09-26 it has turned at 14 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $38.12 | Resistance | 0.5% above the last close | turned there twice · 2026-03-23 to 2026-06-26 |
| $37.23 | Support | 1.9% below the last close | turned there twice · 2025-11-11 to 2026-07-23 |
| $35.23 | Support | 7.1% below the last close | turned there three times · 2026-02-12 to 2026-04-23 |
| $43.33 | Resistance | 14.3% above the last close | turned there twice · 2026-07-02 to 2026-07-29 |
| $32.02 | Support | 15.6% below the last close | turned there four times · 2025-12-22 to 2026-05-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · trendless / choppy (low ADX) · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$48.83 range $47.00 – $50.00; median $49.50
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GRDN
- Consensus EPS estimate$0.315 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Government and private efforts to lower pharmaceutical costs and limit pharmacy reimbursements.","Dependence on maintaining and expanding relationships with long-term care facility operators.","Risk of errors in the dispensing or administration of pharmaceuticals and associated liability."]
What changed in the latest 10-Q
AI-assisted comparison of GRDN's 10-Q filed 2026-05-06 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Added disclosure of Class B to Class A conversion: '13,527,437 shares of the Company's Class B common stock automatically converted...into an equal number of shares of the Company's Class A common stock' during Q1 2026 (filed 2026-05-06)
- Added new section 'Follow-On Offering' describing Q1 2026 Offering of 1,020,000 shares at $31.00 per share completed in March 2026, with proceeds used to repurchase and cancel Class A common stock, plus selling stockholders' sale of 5,880,000 shares (filed 2026-05-06)
- Added reference to 'Annual Report on Form 10-K for the year ended December 31, 2025' (filed 2026-05-06)
- Updated pharmacy count from 53 to 61 pharmacies as of March 31, 2026, with 54 full-service pharmacies specified (filed 2026-05-06)
- Updated resident count from approximately 204,000 to approximately 207,000 as of March 31, 2026 (filed 2026-05-06)
- Updated LTCF count from approximately 8,200 to approximately 8,400 (filed 2026-05-06)
- Added new section 'Factors Affecting the Comparability of Our Results of Operations' with subsections on Acquisitions and Inflation Reduction Act (filed 2026-05-06)
- Added description of 2025 acquisitions and their impact on Q1 2026 results (filed 2026-05-06)
- Added Inflation Reduction Act section discussing August 2022 legislation, drug pricing reforms, Medicare Part B and Part D provisions, and CMS guidance (filed 2026-05-06)
- Removed:
- Removed 'Corporate Reorganization and IPO' section that detailed September 27, 2024 IPO specifics, conversion mechanics, and merger consideration (filed 2025-11-10)
- Removed reference to 'Annual Report on Form 10-K for the year ended December 31, 2024' (filed 2025-11-10)
- Reworded:
- Date reference changed from 'September 30, 2025' to 'March 31, 2026' for pharmacy and resident metrics (filed 2026-05-06 vs 2025-11-10)
- Notes:
- The newer filing text appears truncated at 'has since entered three rounds of the Medicare D' and comparison at this point becomes incomplete
- The older filing text includes detailed Corporate Reorganization content that was moved or restructured in newer filing rather than simply removed
Risk Factors
- Added:
- Reference to Annual Report on Form 10-K for the year ended December 31, 2025 (in newer filing, filed 2026-05-06)
- Forward-looking statements risk factor mentioning 'capping the prices for certain drugs' (filed 2026-05-06)
- Financial statements now show March 31, 2026 data (filed 2026-05-06)
- Removed:
- Reference to Annual Report on Form 10-K for the year ended December 31, 2024 (removed in newer filing, filed 2026-05-06)
- Forward-looking statements risk factor about 'the market price of shares of our Class A common stock has experienced, and may in the future experience, substantial volatility due to relatively lower trading volumes and a limited public float' (removed in newer filing, filed 2026-05-06)
- Financial statements showing September 30, 2025 data (removed in newer filing, filed 2026-05-06)
- Reworded:
- Risk factor language changed from 'including by limiting pharmacy reimbursements' to 'including by capping the prices for certain drugs and limiting pharmacy reimbursements' (filed 2026-05-06)
- Bullet point order changed: 'and' moved from end of misuse/off-label use bullet to separate the last two risk factors (filed 2026-05-06)
- Table of Contents page numbers changed: Item 1A moved from page 33 to page 22; Item 4 moved from page 34 to page 23; Item 5 moved from page 34 to page 23; Item 6 moved from page 35 to page 24; Signatures moved from page 36 to page 25 (filed 2026-05-06)
- Notes:
- The comparison focuses on the forward-looking statements section and related balance sheet/income statement data visible in the provided excerpts; the full Risk Factors section (Item 1A) content is not included in either excerpt beyond table of contents references
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for GRDN — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding GRDN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,303,859
- Reported value $199,743,319
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
GRDN had 2,853,089 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for GRDN because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 2,853,089
- Prior settlement (shares) 2,791,798
- Reported change 2.2%
- Days to cover (reported) 9.55
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
- Omnicare (CVS)
- PharMerica
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GRDN vs…
Frequently asked questions
What does GUARDIAN PHARMACY SERVICES INC CLA (GRDN) do?
Guardian Pharmacy Services operates a network of pharmacies that specialize in providing pharmaceutical services and medication management for long-term care facilities (LTCFs). The company focuses on dispensing medications, providing consulting pharmacy services, and integrating pharmacy operations with the clinical needs of residents in long-term care settings.
What sector is GUARDIAN PHARMACY SERVICES INC CLA (GRDN) in?
GUARDIAN PHARMACY SERVICES INC CLA (GRDN) is classified in the Health Care sector. Its industry is Pharmacy Services. It trades on NYSE.
Who are GUARDIAN PHARMACY SERVICES INC CLA's (GRDN) competitors?
Notable peers of GUARDIAN PHARMACY SERVICES INC CLA (GRDN) include CVS Health, Walgreens Boots Alliance, Omnicare and PharMerica. This peer set is informational only — not financial advice.
Is GUARDIAN PHARMACY SERVICES INC CLA (GRDN) overbought or oversold right now?
GUARDIAN PHARMACY SERVICES INC CLA (GRDN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GRDN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.